Beyond Air (XAIR) Competitors

$1.29
0.00 (0.00%)
(As of 05/8/2024 ET)

XAIR vs. DXR, DRIO, APYX, NSPR, GBS, CTSO, LUCD, AMIX, CTCX, and CODX

Should you be buying Beyond Air stock or one of its competitors? The main competitors of Beyond Air include Daxor (DXR), DarioHealth (DRIO), Apyx Medical (APYX), InspireMD (NSPR), GBS (GBS), Cytosorbents (CTSO), Lucid Diagnostics (LUCD), Autonomix Medical (AMIX), Carmell (CTCX), and Co-Diagnostics (CODX). These companies are all part of the "surgical & medical instruments" industry.

Beyond Air vs.

Beyond Air (NASDAQ:XAIR) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Daxor's return on equity of 0.00% beat Beyond Air's return on equity.

Company Net Margins Return on Equity Return on Assets
Beyond AirN/A -199.90% -106.00%
Daxor N/A N/A N/A

In the previous week, Beyond Air's average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company Overall Sentiment
Beyond Air Neutral
Daxor Neutral

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 19.0% of Beyond Air shares are held by company insiders. Comparatively, 60.6% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beyond Air currently has a consensus target price of $10.75, suggesting a potential upside of 733.33%. Given Beyond Air's higher possible upside, analysts clearly believe Beyond Air is more favorable than Daxor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beyond Air
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Daxor
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Beyond Air received 44 more outperform votes than Daxor when rated by MarketBeat users.

CompanyUnderperformOutperform
Beyond AirOutperform Votes
44
68.75%
Underperform Votes
20
31.25%
DaxorN/AN/A

Beyond Air has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beyond AirN/AN/A-$55.82M-$2.13-0.61
DaxorN/AN/AN/AN/AN/A

Summary

Beyond Air beats Daxor on 5 of the 8 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XAIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XAIR vs. The Competition

MetricBeyond AirSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$46.49M$3.86B$5.00B$7.78B
Dividend YieldN/A2.15%2.84%3.96%
P/E Ratio-0.6120.57190.2119.45
Price / SalesN/A63.332,336.7180.42
Price / CashN/A45.3233.5428.62
Price / Book0.924.224.924.39
Net Income-$55.82M$4.65M$105.35M$217.65M
7 Day Performance5.74%-1.52%0.34%1.02%
1 Month Performance-22.75%-5.45%-3.63%-2.68%
1 Year Performance-77.41%8.17%3.34%9.46%

Beyond Air Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
0 of 5 stars
$9.80
flat
N/AN/A$46.45MN/A0.00N/A
DRIO
DarioHealth
1.4241 of 5 stars
$1.63
+1.9%
$5.37
+229.2%
-56.4%$48.36M$20.35M-1.58276Upcoming Earnings
APYX
Apyx Medical
3.5324 of 5 stars
$1.41
+0.7%
$6.17
+337.4%
-61.2%$48.84M$52.35M-2.61252News Coverage
NSPR
InspireMD
2.0826 of 5 stars
$2.10
-0.9%
$4.85
+131.0%
+43.1%$49.61M$6.21M-1.9465
GBS
GBS
0 of 5 stars
$2.89
+16.5%
N/A+428.3%$43.03M$440,000.00-5.167Gap Up
CTSO
Cytosorbents
1.0132 of 5 stars
$0.93
flat
$2.50
+168.2%
-69.2%$50.63M$36.35M-1.46186Analyst Forecast
News Coverage
Gap Up
LUCD
Lucid Diagnostics
2.0181 of 5 stars
$1.03
-1.0%
$2.75
+167.0%
-40.3%$51.27M$2.43M-0.8170Upcoming Earnings
Gap Down
High Trading Volume
AMIX
Autonomix Medical
0 of 5 stars
$2.81
-10.8%
N/AN/A$52.80MN/A0.001Upcoming Earnings
Gap Down
CTCX
Carmell
0 of 5 stars
$2.05
+1.5%
N/AN/A$39.46MN/A0.009Gap Up
CODX
Co-Diagnostics
3.2314 of 5 stars
$1.26
flat
$2.50
+98.4%
-11.6%$39.39M$6.81M-1.04155Gap Down

Related Companies and Tools

This page (NASDAQ:XAIR) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners